Every Onyx debate resolves on a single number due in November 2026.

• The break. FY26 operating margin fell to 4.89% from 16.76% on revenue that grew 12% to $7.4M — a 1,200 bp collapse filed with no write-down, no restructuring charge, and no management commentary.
• The signal. H2FY26 OPM lifted 430 bp to 7.02% on essentially flat half-on-half revenue ($3.7M → $3.7M). Costs flat, revenue flat, margin up — the geometric signature of fixed-cost absorption from the Unit II cephalosporin ramp.
• The decision. The H1FY27 print due ~14 November 2026 is named by every specialist as decisive: above 12% would reframe FY26 as ramp absorption; at or below 7% would confirm a sub-scale price-taker. 178 days away.

Revenue compounded 16% per year for four years, then operating leverage went the wrong way.

Unit II's cephalosporin segregation suite started absorbing depreciation, interest, and WHO-GMP staffing costs before its dry-powder volumes caught up — textbook CDMO ramp lag. The harder problem is working capital: tier-1 buyers (Sun, Mankind, Aristo, Dr Reddy's, Macleods) now pay 144 days out, supplier finance is exhausting (DPO 156 → 125), cash fell from $1.0M to $0.43M, and short-term borrowings rose 84%. ROCE collapsed from 12.16% to 1.14% — below the 8–9% cost of debt the company itself pays.

An SME-listed micro-cap with the CFO on the audit committee filed a loss with no MD&A and no concall.

• The silence. Management filed the 14 May 2026 FY26 audited result — PAT swung from +$0.58M to a $25,000 loss — without commentary. The FY25 Director's Report (May 2025) had promised "exceptional performance" and "better operation and financial performance in FY2026." Twelve months later, no acknowledgement, no concall, no forward statement.
• Cash quality. Five-year cumulative net profit $1.5M; five-year cumulative operating cash flow $0.46M — 29 cents of cash on every reported dollar. The gap sits in receivables ($2.9M against a $6.0M market cap) with no bad-debt reserve disclosed, and a $0.30M Drawing Power reconciliation gap flagged in Note 38 of the FY25 annual report.
• Informed money left. FII holding fell from 8.72% at the November 2024 IPO to 1.07% by March 2026 across four consecutive disclosure patterns; shareholder count fell from 1,181 to 586. Promoters held 65.10% steady but bought nothing at sub-book.

The tape prices FY26's 4.9% margin as steady state. The half-on-half pattern says ramp.

• Sequence beats cross-section. The 1.05× book multiple anchors to the FY26 full-year 4.89% margin. It does not price the half-on-half: revenue flat at $3.7M, costs flat, margin lifting 430 bp from 2.72% to 7.02%. That is mechanical fixed-cost absorption, not a moat-less ceiling.
• The receivables frame is incomplete. Bears single out DSO 144 in isolation. Integrated, Onyx's cash-conversion cycle of 119 days is the leanest in the listed Indian sterile-CDMO peer set — Gland 255, Caplin 194, Cohance 159. The same tier-1 buyers stretch every Indian CDMO; the level is industry-comparable, the direction is what matters.
• Akums is mechanical, not imminent. Onyx's top-ranked competitor is also a customer with $37M of CDMO capex planned. The capex spans multiple dosage forms; a new cephalosporin segregation suite is an 18–24 month build-plus-WHO-GMP certification cycle, not an announcement that lands tomorrow.